Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 04 tags : Cancer save search
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-04 (Crawled : 20:00) - biospace.com/
RAIN | $1.21 0.0% 3.7M
|
Manufacturing
|
| O: 0.39%
H: 1.1%
C: -4.41%
molecular cancer conference
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CUE | $1.51 -3.82% -3.97% 160K
|
Health Technology
|
| O: -1.16%
H: 0.42%
C: -9.97%
presentation immunotherapy biopharma therapy cancer
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CADL | $5.94 7.22% 6.73% 450K
|
|
| O: -0.48%
H: 2.4%
C: -5.36%
immunotherapy therapy cancer
C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
Published: 2021-10-04 (Crawled : 13:15) - biospace.com/
ARAY | $2.22 2.3% 2.25% 410K
|
Health Technology
|
| O: 0.49%
H: 0.49%
C: -1.23%
treatment cancer breast cancer
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
Published: 2021-10-04 (Crawled : 13:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 1.31%
H: 2.69%
C: -1.89%
therapy cancer trial keytruda
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
Published: 2021-10-04 (Crawled : 13:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: -4.78%
H: 2.41%
C: 0.0%
phase 2 positive hpv cancer biotech iot trial enroll
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-10-04 (Crawled : 11:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: 0.82%
H: 0.94%
C: -10.32%
immunotherapy therapy cancer biotech iot
Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)
Published: 2021-10-04 (Crawled : 05:00) - profoundmedical.com
PROF | News | $7.85 -5.42% -5.73% 17K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: -3.86%
prostate cancer cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.